Literature DB >> 17378816

Cost-effectiveness of human papillomavirus testing after treatment for cervical intraepithelial neoplasia.

V M H Coupé1, J Berkhof, R H M Verheijen, C J L M Meijer.   

Abstract

OBJECTIVE: To compare current cytological follow up of women treated for high-grade cervical intraepithelial neoplasia (CIN) with follow up by high-risk human papillomavirus (HPV) testing together with cytology.
DESIGN: A cost-effectiveness modelling study.
SETTING: Gynaecology clinics in the Netherlands. POPULATION: Women treated for high-grade CIN.
METHODS: A Markov model was developed to compare six follow-up strategies with HPV testing with current cytological follow up at 6, 12, and 24 months. Model parameter estimation was based on three Dutch follow-up studies and a Dutch population-based screening cohort. MAIN OUTCOME MEASURES: The number of CIN2/3 cases missed after 5 years follow up, the number of diagnostic procedures, and costs involved.
RESULTS: Strategies with adjunct HPV testing were more effective than current follow up (reduction in missed CIN2/3 cases 32-77%, corresponding to a number needed to treat of 192-455) and less inconvenient (reduction in repeat smears 28-65%). A particularly attractive strategy was HPV testing alone at 6 months and both HPV and cytological testing at 24 months after treatment. This strategy yielded a high detection rate of post-treatment CIN, did not lead to an increase in colposcopy rate, and was 49 Euro per woman cheaper than the current strategy.
CONCLUSIONS: Our model supports the use of high-risk HPV testing for monitoring women treated for high-grade CIN.

Entities:  

Mesh:

Year:  2007        PMID: 17378816     DOI: 10.1111/j.1471-0528.2007.01265.x

Source DB:  PubMed          Journal:  BJOG        ISSN: 1470-0328            Impact factor:   6.531


  7 in total

1.  The value of HPV-HR DNA testing during the follow-up after treatment of CIN3/AIS.

Authors:  Maja Banović; Vesna Mahovlić; Kristina Meljanac Salopek; Vladimir Banović; Ivan Babić; Slavko Orešković; Damir Babić
Journal:  Pathol Oncol Res       Date:  2014-11-29       Impact factor: 3.201

2.  Five-year risk of recurrence after treatment of CIN 2, CIN 3, or AIS: performance of HPV and Pap cotesting in posttreatment management.

Authors:  Hormuzd A Katki; Mark Schiffman; Philip E Castle; Barbara Fetterman; Nancy E Poitras; Thomas Lorey; Li C Cheung; Tina Raine-Bennett; Julia C Gage; Walter K Kinney
Journal:  J Low Genit Tract Dis       Date:  2013-04       Impact factor: 1.925

Review 3.  Systematic review of model-based cervical screening evaluations.

Authors:  Diana Mendes; Iren Bains; Tazio Vanni; Mark Jit
Journal:  BMC Cancer       Date:  2015-05-01       Impact factor: 4.430

4.  HPV self-sampling in the follow-up of women after treatment of cervical intra-epithelial neoplasia: A prospective study in a high-income country.

Authors:  Manuela Viviano; Pierre Vassilakos; Ulrike Meyer-Hamme; Lorraine Grangier; Shahzia Lambat Emery; Manuela Undurraga Malinverno; Patrick Petignat
Journal:  Prev Med Rep       Date:  2021-09-20

5.  Practical Model for Residual/Recurrent Cervical Intraepithelial Lesions in Patients with Negative Margins after Cold-Knife Conization.

Authors:  Wei Chen; Yajie Dong; Lu Liu; Lin Jia; Lihua Meng; Hongli Liu; Lili Wang; Ying Xu; Youzhong Zhang; Xu Qiao
Journal:  J Clin Med       Date:  2022-09-24       Impact factor: 4.964

6.  Cost effectiveness of human papillomavirus test of cure after treatment for cervical intraepithelial neoplasia in England: economic analysis from NHS Sentinel Sites Study.

Authors:  Rosa Legood; Megan Smith; Jie-Bin Lew; Robert Walker; Sue Moss; Henry Kitchener; Julietta Patnick; Karen Canfell
Journal:  BMJ       Date:  2012-10-31

7.  Early human papillomavirus testing predicts residual/recurrent disease after LEEP.

Authors:  Aeli Ryu; Kyehyun Nam; Jeongja Kwak; Jeongsig Kim; Seob Jeon
Journal:  J Gynecol Oncol       Date:  2012-09-19       Impact factor: 4.401

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.